MSP 4018
Alternative Names: MSP-4018Latest Information Update: 09 Jan 2024
At a glance
- Originator Mindset Pharma
- Developer Otsuka America Pharmaceutical
- Class Behavioural disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurological disorders; Psychiatric disorders
Most Recent Events
- 01 Jan 2024 Mindset Pharma has been acquired and merged into Otsuka America Pharmaceutical
- 19 Apr 2022 Mindset Pharma files for patent protection for N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) derived candidates
- 20 Sep 2021 Mindset Pharma has patents pending for MSP 4018 in USA, prior to September 2021